Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Reuters

2025/06/02

<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540089762"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540089762\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540089762?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540089762","market":"us","top_or_hot":-1,"title":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLAY","symbol_name":"Relay Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLNQVCH:1","article_id":"2540089762","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540089762","pubTimestamp":1748862036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology  2025 Annual Meeting, the data demonstrates a median progression-free survival  of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLAY":"Relay Therapeutics","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4563":"昨日强势股","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Relay Therapeutics宣布启动RLY-2608治疗乳腺癌的3期ReDiscover-2研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RLAY":0.9},"content_text":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    \n\n        Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}